Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

Anti-Epidermal Growth Factor-like Domain 7 Monoclonal Antibody MEGF0444A

Known as: MEGF 0444A, MEGF0444A 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Abstract Lessons Learned. These negative phase II results for parsatuzumab highlight the challenges of developing an agent… Expand
  • figure 1
  • figure 2
  • table 1
2012
2012
e13000 Background: Epidermal growth factor-like domain 7 (EGFL7), is a vascular-restricted, tumor selective, extracellular matrix… Expand
2011
2011
2514 Background: Epidermal growth factor-like domain 7 (EGFL7), is a vascular-restricted, tumor selective, extracellular matrix… Expand
2011
2011
  • Y. Xin, M. Gordon, +6 authors S. Bai
  • Journal of clinical oncology : official journal…
  • 2011
  • Corpus ID: 11041923
2586 Background: Monoclonal antibody therapeutics in oncology are most frequently dosed using body weight (BW)-based dosing… Expand
2011
2011
2539 Background: DCE-MRI allows for the functional analysis of tumor microcirculation and composition, and has been used to… Expand
2011
2011
2614 Background: Epidermal growth factor-like domain 7 (EGFL7), is a vascular-restricted, tumor selective, extracellular matrix… Expand